HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (“MabCure”), a diagnostic company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, is featured in the September issue of GEN (Genetic Engineering & Biotechnology News). The article, written by MabCure CEO, Dr. Amnon Gonenne, entitled “Searching for Appropriate Cancer Biomarkers,” describes how tumor-specific antibodies could positively impact diagnosis, imaging, and therapy.
